1995
DOI: 10.1183/09031936.95.08121991
|View full text |Cite
|
Sign up to set email alerts
|

Pulmonary hypertension, mechanisms and treatment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

1996
1996
2013
2013

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 6 publications
(4 reference statements)
0
1
0
Order By: Relevance
“…The disorder can be classified as pulmonary arterial hypertension (PAH), pulmonary veno-occlusive disease, pulmonary hypertension due to left heart disease, lung diseases and hypoxia, chronic pulmonary thromboembolism and pulmonary hypertension with unclear mechanisms [3]. Better understanding of the pathophysiology of PAH has led to the introduction of three main classes of drugs that target vasoconstriction, vascular remodelling and in situ thrombosis [4][5][6]. These include phosphodiesterase inhibitors, endothelin receptor blockers and prostanoids [1,7].…”
Section: Introductionmentioning
confidence: 99%
“…The disorder can be classified as pulmonary arterial hypertension (PAH), pulmonary veno-occlusive disease, pulmonary hypertension due to left heart disease, lung diseases and hypoxia, chronic pulmonary thromboembolism and pulmonary hypertension with unclear mechanisms [3]. Better understanding of the pathophysiology of PAH has led to the introduction of three main classes of drugs that target vasoconstriction, vascular remodelling and in situ thrombosis [4][5][6]. These include phosphodiesterase inhibitors, endothelin receptor blockers and prostanoids [1,7].…”
Section: Introductionmentioning
confidence: 99%